Overview

A Study of Intravenous INO-1001 Plus Oral Temozolomide to Evaluate Tolerability, Safety, and Pharmacokinetics in Patients With Melanoma

Status:
Terminated

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

This is a prospective, open-label, non-randomized, multicenter study in adults, aged eighteen (18) or older, with newly-diagnosed or recurrent unresectable Stage III or Stage IV melanoma. A maximum of 18 subjects will be enrolled in Stage 1 of this study. (Stage 1 completed enrollment in June 2006.) A maximum of 39 subjects will be enrolled in Stage 2 of this study.

Phase:

Phase 1

Details

Lead Sponsor:

Genentech, Inc.

Treatments:

Dacarbazine
Temozolomide